A Hit-to-Lead optimisation programme was carried out on a high throughput screening hit, the thiazolopyrimidine 1, resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist 29. (c) 2005 Elsevier Ltd. All rights reserved.
OKAFOR C. O., J. HETEROCYCL. CHEM., 1980, 17, NO 7, 1587-1592